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POPULÄRVETENSKAPLIG SAMMANFATTNING 
Flercelliga organismer är uppbyggda av flera sorters celler med många olika funktioner. 
Vissa av cellerna är specialiserade på att få hjärtat att slå, medan andra celler står beredda ifall 
ett sår behöver läkas, eller ser till att blod kan transporteras så att alla organismens celler kan 
få näring. För att organismens celler ska fungera på ett korrekt sätt behöver cellerna 
kommunicera med varandra. Detta sker via signalsubstanser som utsöndras av den cell som 
vill något. Signalen tas emot av en mottagare - en receptor, som finns på mottagarcellen. 
Mottagarcellen reagerar på signalen, t.ex. genom att dela sig, röra på sig eller skicka ut nya 
signaler. Ibland kan det bli fel i cellernas kommunikation, vilket är vanligt i olika 
sjukdomssammanhang. Felet kan bero på att cellerna har blivit skadade så att de inte längre 
kan signalera normalt, som vid cancer, då enstaka celler förlorar förmågan att svara på vissa 
signaler, med följden att de börjar växa på ett okontrollerat sätt.  
En familj av signalsubstanser är PDGF (Platelet-Derived Growth Factor), som normalt 
utsöndras från bland annat blodkärlsceller. PDGF-familjen består av fyra olika typer av 
PDGF substanser som alla har olika funktioner i organismen, men gemensamt är att de 
fungerar som tillväxtfaktorer. PDGF-signaleringen är livsviktig under fosterstadiet, där 
specifika celler får signaler om hur de ska dela sig och vandra till platser där de behövs. Utan 
korrekt PDGF-signalering utvecklas därför inte organismen som den ska. En annan viktig 
funktion för PDGF är att se till att blodkärlen är omslutna av stödjande celler, så att de håller 
ihop och inte läcker. Dessutom är PDGF involverat i cancer, där för mycket PDGF-
signalering kan leda till att det bildas cancerceller, eller att cancerceller stimuleras att växa. 
Den här avhandlingen handlar om PDGF-D, den senast upptäckta medlemmen i PDGF-
familjen, som även är den substans man vet minst om. För att försöka förstå vad PDGF-D gör 
har vi konstruerat en genetiskt modifierad musstam som saknar PDGF-D. I artikel I 
undersöker vi den musstammen och visar att PDGF-D inte är nödvändigt för normal 
fosterutveckling, men att avsaknaden av PDGF-D resulterar i ett lite förhöjt blodtryck. Vi 
visar även att PDGF-D finns i blodkärl, både i cellagret som utgör själva ”röret” och i 
stödjeceller som sitter runt om, samt att vissa av stödjecellerna är beroende av PDGF-D för 
att fungera optimalt. I Artikel II visar vi att en speciell form av cancer i bukspottkörteln som 
saknar PDGF-D växer mindre. Vi kom fram till att det berodde på att PDGF-D signalering 
påverkar en mycket liten cellpopulation, som påverkar tumörens tillväxt och utveckling. 
Slutligen, i Artikel III fokuserar vi på NRP1, som fungerar som en tilläggsreceptor till en 
annan receptor för PDGF-D och vi visar att NRP1 kan påverka PDGF-D signalering.  
De forskningsfynd som presenteras i avhandlingen utvidgar kunskapen om hur PDGF-
familjen fungerar och signalerar. Den ökade förståelsen för hur cellerna kommunicerar med 
hjälp av PDGF behövs för att kunna utveckla nya, bättre läkemedel mot sjukdomar där bland 
annat blodkärlen är påverkade, till exempel åderförfettning och cancer.   
ABSTRACT 
The platelet-derived growth factors (PDGF) and their receptors (PDGFRs) regulate growth 
and migration in cell populations of mesenchymal origin. The PDGF signaling system is vital 
for development, in neural crest formation, in organogenesis, and in maturation of the 
microvasculature. In the adult, PDGFs are needed to maintain homeostasis. They are also 
released in response to tissue injury, where they promote wound healing and 
neovascularization. In the adult, high expression of PDGFs is also seen in atherosclerosis, 
fibrosis and in malignant conditions. The PDGF family consists of four ligands that are 
present as dimers (PDGF-AA, PDGF-BB, PDGF-CC and PDGF-DD) and two tyrosine 
kinase receptors (PDGFRα and PDGFRβ). Upon ligand binding, receptor dimerization and 
auto-phosphorylation is induced. Downstream signaling leads to immediate effects in 
receptor-expressing cells, but also prolonged effects through modulation of transcription are 
seen.  
PDGF-D is the most recently found ligand and its biological function is still unclear, although 
its signaling receptor PDGFRβ is mainly expressed in vascular smooth muscle cells, thus 
indicating a vascular role also for PDGF-D. PDGF-B, the other PDGFRβ ligand, also binds to 
PDGFRα, thus making PDGF-D the only ligand that signals exclusively through PDGFRβ. 
Moreover, PDGF-D expression is uncoupled from its signaling as it is released in a latent, 
full-length form requiring proteolytic cleavage for receptor binding. In contrast, the other 
PDGFRβ ligand, PDGF-B, is active already upon release. 
PDGF signaling has been studied through a multitude of genetically modified animals, and 
these studies have contributed greatly to the understanding of PDGF function. In the work 
included in this thesis, we present the PDGF-D knockout mouse strain, and characterize the 
expression and function of PDGF-D in vivo, in both physiological conditions and in the 
tumor setting. We confirm that PDGF-D has a vascular expression pattern, and show that it is 
mainly expressed in arteries and in the endothelium, but it can also be expressed in vSMCs. 
We show that targeted deletion of PDGF-D affected an NG2-expressing pericyte population 
in the heart, and that animals lacking PDGF-D have slightly elevated blood pressure. 
Furthermore, we present evidence that paracrine PDGF-D signaling from the vasculature 
induces the production of factors from a rare PDGFRβ-expressing tumor cell subpopulation, 
thereby contributing to tumor growth. We also define a possible role for a co-receptor in this 
process. Finally, we present NRP1 as co-receptor for PDGF-D in PDGFRβ signaling, and 
thereby also suggest a mechanistic basis for PDGF-D-specific PDGFRβ-NRP1 complex 
formation and signaling. The addition of NRP1-mediated modulation adds complexity to the 
current model of PDGF-D/PDGFRβ signaling. Ultimately, these findings will lead to a better 
understanding of the role(s) of PDGF-D signaling, and thereby to improved development of 
tailored therapeutics for conditions where PDGF-D signaling might be dysregulated, such as 
atherosclerosis and cancer. 
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1 INTRODUCTION 
The family of platelet-derived growth factors (PDGFs) is important during development, in 
adult physiology, and in a number of pathological conditions, including atherosclerosis, 
fibrosis, and cancer. They act by inducing survival, proliferation and migration in cells of 
mesenchymal origin, and are often released upon tissue injury (reviewed in (1)). Initially, the 
PDGF family consisted only of PDGF-A and -B, but in 2000 and 2001, two more ligands 
were unexpectedly discovered. These novel ligands were named PDGF-C and PDGF-D, and 
added new complexity to PDGF signaling, which is still not completely understood. 
Moreover, the biological function of the latest member in the PDGF family, PDGF-D, is 
obscure. The aim of the work described in this thesis was to investigate the biological role(s) 
and functional relevance of PDGF-D, both during physiological and pathological conditions, 
and thereby enhance the understanding of PDGF signaling. 
This introductory chapter will mainly focus on what is known about the structure, regulation 
and function of the PDGFs and their receptors in physiological and pathological settings. It 
will also introduce NRP1 and its known interactions with PDGFs, as this thesis describes a 
novel role of NRP1 as a co-receptor for PDGF-D. 
1.1 THE PDGF SYSTEM 
The PDGF family of growth factors consists of four ligands, PDGF-A, -B, -C, and -D, and 
two receptors PDGFRα and PDGFRβ (2). The PDGFs were discovered already in the 1970’s, 
and were among the first growth factors to be characterized, and the PDGF/PDGFR signaling 
have served as a model system for other growth factor families signaling through tyrosine 
kinase receptors, and is one of the most well-studied ligand-receptor systems. 
1.1.1 PDGF ligands, structure and activation 
The four PDGF ligands belong to the vascular endothelial growth factor (VEGF)/PDGF 
superfamily, which all share a conserved growth factor domain (GFD) with eight conserved 
cysteine residues that are important for disulphide bond formation and protein structure (3). 
Grouping by homology divides the PDGFs in two structural subgroups, also corresponding to 
the order in which the PDGFs were discovered. Thus, PDGF-A and PDGF-B form one 
subgroup where their N-terminal signal peptide is followed by a pro-peptide, the GFD and a 
C-terminal basic retention motif that allows for interactions with the extracellular matrix. 
PDGF-C and PDGF-D form a second subgroup as they have an additional N-terminal CUB 
domain (named after the first three proteins it was found in; Complement subcomponents 
C1r/C1s, Urchin EGF-like protein and Bone morphogenic protein 1), followed by a hinge 
region and the GFD, but no C-terminal retention motif (reviewed in (2)). The CUB-domains 
block receptor binding of the GFD, and need to be proteolytically removed before receptor 
binding and signaling can be induced. CUB domains are generally found in extracellular and 
membrane-associated proteins involved in developmentally regulated processes and are 
thought to mediate extracellular binding (reviewed in (4) and in (2)).  
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The PDGF ligands are encoded by four separate genes, which are located on different 
chromosomes. The Pdgfd gene is very large and spans over 200.000 base pairs, half of which 
are in the massive first intron. It is located on chromosome 11q22.3 in humans, and on 9A1 in 
the mouse (5-7) and is comprised of seven exons. Exon 1 encodes the signal peptide, exon 2-
3 the CUB domain, exon 4 the hinge region between the two structural domains, and lastly, 
exon 6-7 encode the GFD (6, 8).  
Biologically, the PDGFs occur as homo- or heterodimers (PDGF-AA, -AB, -BB, -CC, and -
DD), which all require proteolytic processing before they can bind to their receptors. PDGF-
A and -B are processed and activated prior to secretion, while PDGF-C and -D are activated 
extracellularly (reviewed in (2)). In PDGF-A and PDGF-B, the N-terminal propeptides are 
cleaved off intracellularly before secretion, by the dibasic-specific proprotein convertase furin 
(reviewed in (2)). In contrast to PDGF-A and PDGF-B, PDGF-C and PDGF-D are secreted in 
their full-length form, in which the CUB domains prevent receptor binding and needs to be 
cleaved off before receptor binding and signaling can occur. The extracellular cleavage is 
performed by serine proteases. PDGF-C is cleaved by tissue plasminogen activator (tPA), 
while PDGF-D is cleaved by urokinase plasminogen activator (uPA) and matriptase. 
However, there might be other proteases capable of cleaving PDGF-C and PDGF-D that are 
still unknown. The cleavage site for PDGF-D is located in the hinge region (R247/R249) 
between the CUB and GFD domains (9-11). 
In addition to their full-length forms, PDGF-A and PDGF-B also exist in isoforms without 
the C-terminal retention motif; PDGF-A has an alternative splicing form, encoded by exons 
1-5 and the short (3 amino acids) exon 7, while in PDGF-B, the retention motif can be 
removed by post-translational or extracellular processing (12-15). No additional isoforms 
have been reported for PDGF-C, but several splicing forms have been reported for PDGF-D. 
In human, the main isoform consists of 370 amino acids, and the full-length peptide chain 
had a calculated molecular weight of ~40.3 kDa migrates on SDS-PAGE as a Mr 90 kDa 
dimer, or as a Mr 55 kDa monomer (5). The cleaved, activated dimer migrated at Mr 35 kDa, 
and the cleaved, activated monomer at Mr 20 kDa (6). PDGF-D has a second splice variant of 
364 amino acids, lacking 6 amino acids in the region upstream of the CUB-domain (5), and in 
mouse, a third splicing variant has been reported, which is lacking exon 6 and has no 
mitogenic properties in the GFD (16). Little is known about these alternate splicing forms of 
PDGF-D, and therefore, only the first isoform will be discussed in this work. 
1.1.2 PDGF receptors, structure and signaling 
PDGFs act by binding to the tyrosine kinase receptors PDGFRα and PDGFRβ, which induces 
downstream signaling and thereby modulates cellular functions. The PDGF receptors form 
dimers upon ligand binding, with different specificity for the ligands. PDGF-AA, -BB, -AB 
and -CC all bind to the PDGFRα homodimer and PDGF-BB and -DD bind to the PDGFRβ 
homodimer (reviewed in (2)). Each receptor monomer has five extracellular immunoglobulin 
(Ig)-like domains, whereof the three N-terminal ones are involved in ligand binding, followed 
by a trans-membrane domain and an intracellular split tyrosine kinase domain (reviewed in 
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(1)). Binding of a PDGF ligand to a receptor monomer induces receptor dimerization, 
whereupon conformational changes lead to auto-phosphorylation of the intracellular tyrosine 
residues and enables binding of SH2 (Src Homology 2) domain signaling molecules. 
Structural differences between the receptor monomers affect the binding site locations and 
affinities for SH2, and thus also the downstream signaling. 
The PDGF receptor dimers formed upon ligand binding have different specificities for the 
ligand dimers, and while PDGF-AA, -BB, -AB and -CC all bind to the PDGFRα homodimer 
PDGF-BB and -DD bind to the PDGFRβ homodimer (reviewed in (2)). All ligand dimers, 
except PDGF–AA, can bind to the PDGFRαβ heterodimer in vitro, although a biological 
relevance of this receptor dimer has not yet been established in physiological conditions 
(reviewed in (2)). However, PDGFRαβ dimers are present in certain tumors, and it is possible 
that also PDGF-DD signals through the heterodimeric receptor complex under pathological 
conditions (6, 17).  
Activated PDGFRs interact with different families of SH2-domain containing molecules; 
some have enzymatic activity (Src, RasGAP, SHP-2, PLC-γ), others are adaptor molecules 
(Grb2, Nck, Shc, Crk, Alix and subdomains of phosphatidylinositol 3’-kinase (PI3K)) leading 
Figure 1. PDGF processing and secretion. PDGF-A and PDGF-B propeptides are cleaved off intracellularly by furin 
and other proprotein convertases. PDGF-Along and PDGF-B are kept close to the cell of origin through ECM binding of 
their C-terminal retention motifs. PDGF-Ashort is diffusible. The PDGF-B C-terminal retention motif can be cleaved off 
to yield a diffusible PDGF-B. PDGF-C and PDGF-D are secreted in their inactive, diffusible forms, and require 
proteolytical removal by serine proteases of their CUB-domains to become activated. 
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to downstream signaling. PDGFRs also bind signaling enhancers (NHERF), and activate 
transcription factors (STAT family) (reviewed in (1) and in (18)). An important PDGFR-
induced pathway is the diverse PI3K pathway, which mediates actin re-organization and 
migration, as well as proliferative and anti-apoptotic responses, through Akt-mediated 
activation of the transcription factor NF-κB. Other responses induced by PDGFRs are PLC-γ-
mediated Ca2+ mobilization, and Ras and Src mediated activation of the Myc and Erk/MAP 
kinase pathways that promote proliferation (reviewed in (1)). The signaling outcome also 
depends on target cell-specific intracellular signaling pathways, and crosstalk between 
different pathways, which in some cases even counteract each other (reviewed in (1)). Most 
pathways are induced by all three PDGFR dimers, but the PDGFRβ intracellular domain is 
more potent in inducing migration, and also has unique signaling capacities needed for mural 
cell function (19).  
Following PDGFR activation and adaptor protein binding, receptors are removed of from the 
cell surface by endocytosis. Vesicle forming proteins named clathrins are recruited to the 
PDGFR cytosolic domains to make them accumulate in clusters, which are subsequently 
reabsorbed into the cell and sorted for recycling or lysosomal degradation (reviewed in (20) 
and in (18)). 
Figure 2. PDGF receptor specificity. All PDGFs except PDGF-D bind to PDGFRα, but only PDGF-B and PDGF-D 
bind to PDGFRβ. PDGF-AB, PDGF-BB, PDGF-CC and PDGF-DD can bind to the PDGFRαβ heterodimieric receptor, 
but it is still unclear whether this receptor has a physiological relevance. 
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1.2 FUNCTIONAL ASPECTS OF PDGF SIGNALING 
The PDGF system have been extensively studied in vitro and in vivo, and is known to be of 
vital importance during development, as both PDGFR null mice phenotypes are embryonic 
lethal. PDGFRα signaling is indispensable in organogenesis, and PDGFRβ signaling is 
crucial for the development of the vascular system. The PDGFRs are expressed in cells of 
mesenchymal origin, such as fibroblasts, smooth muscle cells and pericytes (a perivascular 
supportive cell type), which are often found in connective tissues, while ligands are mostly 
expressed in neighbouring cells. Knowledge of the sites of expression for each of the 
effectors is necessary when trying to understand a functional role, as this often reflects sites 
of biological implications. Other important parts of the regulation include proteolytic 
activation of the ligands, bioavailability and interactions of the ligands with the extracellular 
matrix (ECM). 
1.2.1 Expression and regulation 
PDGFRα, PDGF-A and PDGF-C are expressed already in early embryogenesis, and in 
greater abundance than the more vascular PDGFRβ, PDGF-B and PDGF-D during the early 
stages of development (reviewed in (2)). Both PDGFRs are expressed by mesenchymal cells, 
PDGFRα particularly by certain subtypes of progenitor cells (lung, skin, intestine and 
oligodendrocyte progenitors) while PDGFRβ is strongly expressed in vascular smooth 
muscle cells (vSMCs) and pericytes throughout vascular system (reviewed in (2)). PDGFRβ 
is also often used as a pericyte marker in adult tissue (23). It is noteworthy that no 
physiological function for the PDGFRαβ heterodimer has been identified, and that PDGF and 
PDGFR expression levels are lower in adult (reviewed in (24)). The detailed expression of 
the ligands is complex, but in general, PDGF-B is expressed by endothelial cells, 
megakaryocytes and neurons while PDGF-A and PDGF-C are expressed in epithelial cells, 
muscle, and neuronal progenitors with a partial overlapping expression pattern. Their 
expression patterns have been reviewed in detail (2). 
The expression pattern of PDGF-D, the most recently found PDGF family member, is not as 
well characterized as for the other PDGFs. However, Pdgfd messenger ribonucleic acid 
(mRNA) is known to be present in most adult tissues in both human, rat and mouse (5, 6, 25) 
further discussed in Paper I). The cellular sources of PDGF-D are not very well described, 
probably as a consequence of lack of both good commercial antibodies and in situ 
hybridization probes against human and especially mouse PDGF-D. Moreover, until our 
recent publication of the Pdgfd–/– mouse strain with a LacZ reporter gene expressed under the 
Pdgfd promoter, reporter mice have also been lacking (see Paper I (26)). In spite of the lack 
of good commercial tools for histological detection of PDGF-D, there are a number of reports 
of PDGF-D expression. These observations are summarized below, in relation the expression 
of PDGFRβ and PDGF-B. 
Similar to PDGF-B and PDGFRβ, PDGF-D is expressed at low levels in the normal adult 
vasculature, although there have been some discrepancies regarding its exact localization. 
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PDGF-D expression has been reported in all three vascular layers (endothelium, tunica 
media, tunica adventitia), by endothelial cells, vSMCs and fibroblasts (8, 27, 28). During 
development, PDGF-D and PDGFRβ are co-expressed in arterial vSMCs, and both are 
present in blood vessels lining the vertebra, as well as in skin, skeletal muscle, liver, and lung 
(29). The same study also reported PDGF-D mid-gestational expression in epicardial and 
endocardial cardiomyocytes, and in myocardium, whereas cardiac PDGFRβ was mainly 
observed in the vasculature (29). In the developing avian heart, PDGFRβ expression has been 
reported also in the atrio-ventricular cushions that will develop into cardiac valves and 
connect to the septa, while PDGF-B was seen in endothelial cells, vSMCs, nerves and in the 
developing ventricular septum (30). 
In the adult heart, PDGF-B and PDGFRβ levels are very low, but PDGFRβ is present in 
vSMCs (reviewed in (24)). Presence of PDGF-D has been reported in adult myocardium (29). 
In the kidney, PDGFRβ is expressed by glomerular mesangial cells and vSMCs, while 
PDGF-B is expressed by endothelial cells. In developing and adult kidney, PDGF-D 
expression is present in multiple cell types of mesenchymal origin, such as arterial vSMCs 
and fibroblasts, both in mouse and human. PDGF-D is also expressed in neighbouring cells, 
such as glomerular podocytes and other epithelial cells of the nephron (5, 31, 32). The 
glomerulus was recently reported to display a species-specific expression pattern; in human, 
PDGF-D expression was seen in podocytes but not in mesangial cells (specialized glomerular 
pericytes), whereas the opposite was seen in the mouse (32). In the anterior part of the eye 
surrounding the lens, PDGF-D expression has been reported in the epithelial layers of the 
ciliary body and iris, both during development and in adult tissue. PDGFRβ was expressed in 
the epithelium of the lens and cornea and in the mesenchyme surrounding the optic cup 
during development (33, 34). There are also reports on hematopoietic stem cells expressing 
PDGF-D, and adipose-derived stem cells co-expressing PDGF-D and PDGFRβ but not 
PDGF-B (35, 36). PDGF-D expression has also been observed in the rat central nervous 
system, both during development (E16) and in adult tissue (37). 
In summary, PDGF-D is present in both developing and adult tissues, where it is expressed 
both in cells of mesenchymal origin (vSMCs, mesangial cells and fibroblasts) and in 
neighboring cells, such as endothelium and certain epithelial tissues. This expression pattern 
suggests that PDGF-D can act through both paracrine and autocrine modes of signaling. 
Recently, we published a report on a Pdgfd–/– mouse strain, carrying a LacZ reporter gene 
inserted into the PDGF-D gene to characterize the global and vascular expression of PDGF-D 
in detail (26). Our findings are further discussed in Paper I. 
Regulation and modulation of PDGF signaling 
As discussed above, the downstream signaling pathways appear to be similar between the two 
PDGFRs, while the expression of both receptors and ligands appear to be dependent on 
spatial and temporal regulation together with tissue specific environmental factors.  
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During physiological conditions, PDGFs mainly act by paracrine signaling, and 
consequently, the bioavailability of the ligands and receptors in different tissues is a major 
regulatory aspect, which is in turn depending on a multitude of regulatory mechanisms. A 
major regulatory factor for PDGF-C and PDGF-D is proteolytic activation that is needed to 
enable receptor binding (discussed in section 1.1.1). The proteolysis is regulated through 
local expression and activation by tPA, uPA and matriptase, and possibly also by other 
unknown proteases (9, 11, 38). Interactions with extracellular elements serve to prevent 
diffusion and/or receptor activation, and also mediate establishment of signaling gradients 
that are important for chemotaxis (reviewed in (39)). The retention motif bearing isoforms of 
PDGF-A and PDGF-B bind to heparan sulfate, and in blood, PDGF-B availability is also 
regulated through binding of the plasma protein α2-macroglobulin. It is not clear to what 
extent the latently secreted PDGF-C and PDGF-D interact with ECM through their CUB-
domains (reviewed in (2)). However, unpublished observations from our lab indicate that 
full-length PDGF-D is more diffusible than the cleaved, activated growth factor. Signaling 
modulation through crosstalk with other signaling pathways has been described between 
PDGFRβ and the adhesion receptor integrin αvβ3 (reviewed in (1)), thus indicating 
interference with or from cell-cell or cell-ECM contact. Modulation by co-receptors can act 
to block, enhance or alter intracellular signaling pathways or affect receptor availability. For 
PDGFs, this type of interactions have been reported together with low-density lipoprotein 
receptor related protein (LRP) (40), the uPA receptor (uPAR) (41) and Neuropilin 1 (NRP1) 
(42, 43). The role of NRP1 in modulation of PDGFRβ signaling will be further discussed 
below and in Paper III. Receptor availability can be modulated through receptor trafficking 
upon endocytosis. For PDGFRβ, endocytosis has been reported to be modulated by LRP (44) 
and Eph/ephrin signaling (45). Moreover, the metalloproteinase ADAM10 has been 
identified as a sheddase that cleaves off the extracellular domain for PDGFRβ, although a 
functional role of PDGFRβ shedding has not yet been found (46). Receptor autoactivation 
upon increased levels of reactive oxygen species (ROS) can induce PDGFRβ-mediated 
proliferation and migration (47, 48). 
1.2.2 Physiological roles  
A substantial part of the knowledge of the basic PDGF functions are derived from in vitro 
studies, in which the PDGFs have been shown to mediate survival, proliferation and 
migration. There have also been extensive studies of gene expression, using transgenic mouse 
models and different loss- or gain-of-function strategies providing a deeper understanding of 
many complex physiological functions in vivo. During embryonic stages, PDGFs act to guide 
proliferation, recruitment and migration of cells, while in adult tissues, they mainly act to 
maintain homeostasis. In this section, the roles of PDGFs in development and adult tissues 
are discussed, with focus on the vascular function, as this is the main site of expression for 
PDGFRβ, the signaling receptor of PDGF-D 
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PDGFs during development  
Although in vitro studies have shown that the downstream signaling pathways between 
PDGFRα and PDGFRβ largely overlaps, ablation of the two receptors give rise to very 
different phenotypes (reviewed in (49)).  
PDGFRα and PDGF-A ablation gives rise to similar, multifaceted, phenotypes, with defects 
in oligodendrocytes, chondrocytes, neural crest, alveolar SMCs, kidney fibroblasts, 
chorioallantoic plate, Leydig cells, intestinal mesenchyme and dermis. Pdgfa–/– animals die 
perinatally due to respiratory problems, while Pdgfra–/– embryos die already at mid gestation 
(reviewed in (49)). The PDGF-C phenotype is background dependent; Pdgfc–/– mice on a 
129S1/Sv genetic background die perinatally from feeding and respiratory problems due to a 
cleft palate, whereas Pdgfc–/– mice on a C57BL/6 genetic background survive, but display 
cerebral ventricular malformations, abnormal vascularization and skeletal deformations (50, 
51). Loss of both PDGF-A and PDGF-C phenocopies the developmental defects in Pdgfra–/– 
mice (50). 
The Pdgfrb–/– and Pdgfb–/– phenotypes both gives rise to a general loss of vSMCs, and 
embryos die due to internal bleeding around birth with a slightly worse phenotype in  
Pdgfrb–/– animals. Both Pdgfrb–/– and Pdgfb–/– animals also display abnormal cardiac 
innervation (52, 53). Moreover, both PDGFRα and PDGFRβ are needed for cardiac neural 
crest development (reviewed in (2)).  
Given the similar phenotypes of the Pdgfrb–/– and Pdgfb–/– mice, PDGF-D knockout mice 
were not expected to have a severe phenotype, at least not during embryonic development. 
However, there are some slight deviations between the Pdgfrb–/– and Pdgfb–/– phenotypes; 
PDGFRβ-positive pericyte progenitors are present in skeletal muscle, skin and the adrenal 
gland in the less severe Pdgfb–/– mouse phenotype (reviewed in (1)). It has been suggested 
that compensational PDGF-D signaling could be responsible for these phenotypic 
differences.  
Little is known about the developmental role of PDGF-D; expression data indicate the 
presence of PDGF-D in cardiac, renal and cerebellar tissues, and a role in lens formation has 
been suggested (29, 31, 33, 37). Nevertheless, ligands need receptors to exert their functions, 
and with PDGFRβ as the only known receptor for PDGF-D, their functional roles are 
expected to be coherent. PDGFRβ is mainly expressed in vSMCs/pericytes and thus, PDGF-
D is also expected to have a functional role for these cells.  
The role of PDGFRβ in angiogenesis and vascular maturation has been extensively studied 
using different mouse models and reporter genes, leading to the understanding that PDGF-B 
signaling through PDGFRβ is crucial for proper pericyte recruitment and attachment to the 
vasculature (54). During angiogenesis, the endothelium adopts a more active phenotype to 
build new vessels. PDGF-B is secreted from endothelial tip cells at the angiogenic front to 
attract PDGFRβ-expressing pericytes or mural cell progenitors that migrate along the newly 
formed vessel sprouts (54). The tip cells are VEGF-sensitive and instruct neighboring 
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endothelial cells to take on the proliferative stalk cell phenotype through Notch signaling, and 
thereby promote to elongation of the vascular sprouts (55). In the newly formed endothelium, 
PDGF-B signaling through PDGFRβ promotes maturation and stabilization. Moreover, their 
signaling also controls mural cell fate and proliferation (56, 57). Consistently, PDGF-B 
expression is strong also in growing arteries, where mural cells are actively recruited (23, 54). 
Later on, and in the adult stage most endothelial cells display a third, resting phalanx cell 
phenotype (58). Here, stabilizing pericyte-to-endothelial cell signals regulate the endothelial 
proliferation, survival, migration and differentiation, thereby repressing unwanted 
angiogenesis. Vessels that lack pericytes are leaky and have increased capillary diameter. The 
endothelial cells in such vessels display hyperplasia and excessive folding of the luminal 
membrane, accompanied by altered expression of junction proteins (59). Thus, pericytes act 
as negative regulators of endothelial proliferation, and also instructs the endothelium to keep 
a smooth luminal surface membrane (reviewed in (2)).  
As described in section 1.2.1, many stem and progenitor cells also express PDGFs during 
development, and their activity is often regulated by PDGF signaling from neighbouring 
cells. One example is in the Sertoli cells of the testis, where both PDGF-B and PDGF-D are 
expressed and regulate proliferation and migration of spermatogonial cell precursors (60). 
Physiological role in adult  
The embryonic lethality of Pdgfra–/– and Pdgfrb–/– animals has lead to a focus on the 
developmental functions of these receptors. The PDGFRs are expressed in lower levels also 
in adult, dormant tissues (reviewed in (24)), and it has been suggested that the role of PDGF 
signaling is less important in the adult physiology than in the developmental. Consistently, 
pharmacological blocking of PDGFR signaling by the tyrosine kinase inhibitor Imatinib (also 
targeting c-kit and Abl) is tolerated relatively well (61). Imatinib treatment did, however, give 
adverse effects from the gastrointestinal system, accompanied by myalgia and edema, 
indicating sites of PDGFR activation in the adult (61). Indeed, PDGFRα is expressed in the 
gut, and PDGFRβ-expressing perivascular cells control vessel integrity and interstitial fluid 
pressure (62). Interestingly, a PDGF-D neutralizing monoclonal antibody (CR002) has been 
evaluated in a Phase I trial. Antibody-mediated amelioration of proteins produces few side 
effects, and is as close to a knockout that one can get in the human situation (63). 
Nevertheless, PDGFs are needed in adult tissue homeostasis, and mouse models of partial, 
transgenic and conditional loss or gain of function have contributed to the understanding of 
PDGF signaling in adult settings. One important model is the Pdgfbret/ret mouse strain that 
lacks the PDGF-B retention motif, which normally retains the secreted ligand close to the 
endothelial cell, as a chemotactic signal for vSMCs. The Pdgfbret/ret mice survives until adult 
age, but are smaller than its wildtype littermates, and suffers from a vascular phenotype 
leading to renal and retinal dysfunctions. This model has also shown that the PDGF-B 
retention motif is necessary for proper pericyte recruitment and attachment to the capillaries 
(64). Further studies of the Pdgfbret/ret mouse strain has also lead to the understanding that 
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pericytes are needed to maintain the blood brain barrier, and that this is regulated through 
PDGF signaling (65). 
As implied by the name, PDGFs were originally isolated from platelets, where they play an 
important role in wound healing. Platelets store PDGF-A, -B, and -C and other growth and 
clotting factors in α-granules, which are released upon tissue damage, in order to prevent 
blood loss and maintain homeostasis (66, 67). PDGF signaling is needed throughout the 
wound healing process, and contributes to a number of different events including 
inﬂammation, formation of granulation tissue, re-epithelialization, remodeling and 
neovascularization ((66) and reviewed in (1)). PDGF-B has been shown to be especially 
potent and is released from platelets immediately upon wounding, and stimulates the healing 
process through increased fibroblast proliferation, ECM production and neovessel formation 
(reviewed in (2)). Recombinant human PDGF-B (Becaplermin) is used in the clinic to 
enhance wound healing (68). In similarity to PDGF-B, PDGF-D also serves in recruitment 
and proliferation of monocytes/macrophages and vSMCs (69) and stimulates secretion of 
ECM, as well as matrix degradation factors (MMPs/TIMPs) by vSMCs and fibroblasts (70). 
Part of the wound healing process is also neovessel formation, where PDGFs induce secretion 
of VEGFA to promote angiogenesis, which is also guided through hypoxia and ECM 
scaffolding (reviewed in (71)). Other cases when adult physiological angiogenesis is needed 
include the adaptive response of cardiac and skeletal muscle upon physical exercise, and in 
the uterine cycle, where the tissue is shed and rebuilt in a cyclic manner. 
Another function of PDGFRβ-expressing mural cells is in control of interstitial tissue 
pressure, through maintaining vascular impermeability and contraction of ECM, which 
modulated by both PDGF-B and PDGF-D signaling (69, 72). 
PDGFs regulate mesenchymal stem cell functions also in adult tissues. During the uterine 
cycle, PDGFRβ-expressing cells found in perivascular locations have been suggested to be 
responsible not only for angiogenesis but also for the cyclical growth of the endometrium 
(73). A special function in certain stem cells is also seen for PDGF-D. In contrast to PDGF-B, 
PDGF-D is occasionally co-expressed with PDGFRβ, thus facilitating self-maintaining 
autocrine signaling loops that promote proliferation and migration, as seen in adipose tissue 
derived stem cells (74). 
In summary, as a PDGFRβ ligand, PDGF-D may induce responses that overlap with those of 
PDGF-B, such as survival, proliferation, migration, vascular maturation, and regulation of 
interstitial fluid pressure and ECM homeostasis. Thus, there may be some functional 
redundancy in PDGFRβ signaling between PDGF-D and PDGF-B. In consistence, we 
recently reported our finding that the Pdgfd–/– mice display no major phenotype and survive 
to adulthood. However we also reported that PDGF-D appear to be involved in mural cell 
maintenance during physiological conditions, which is further discussed in Paper I (26). 
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1.3 PATHOLOGICAL ASPECTS OF PDGF SIGNALING 
Dysregulation of PDGF activity is seen in a number of common pathological conditions, such 
as fibrosis, atherosclerosis and cancer. To better understand the role of PDGF signaling in 
these conditions, extensive studies have been performed, including different overexpression 
strategies in vivo. These studies indicate that PDGFs have strong impact on the progression of 
these pathologies, through promotion of excessive proliferation, ECM synthesis and 
migratory signals, commonly affecting different types of SMCs and/or fibroblasts. 
1.3.1 Fibrosis 
Fibrosis is a common condition that is mechanistically similar to exaggerated wound healing, 
but also occurs in response other types of tissue damage. The pathological process is 
characterized by excessive deposition of collagens and other ECM components in the 
interstitium, leading to scarring and disruption of tissue function. These events are also firmly 
connected to transforming growth factor β (TGF-β) signaling, which is a very potent inducer 
of ECM secretion (75). Thus, a central player in fibrosis is the fibroblast, a heterogeneous cell 
type that varies between organs, which responds to TGF-β, PDGF, and other stimuli 
(reviewed in (76) and in (2)).  
PDGFs contribute to the fibrotic process by proliferative and chemotactic signaling, 
especially through myofibroblast expansion (reviewed in (77) and in (2)). All four PDGFs are 
upregulated during fibrosis, and cause massive fibrotic responses when overexpressed in 
animal models (reviewed in (2)). High PDGF expression has been described in pulmonary, 
hepatic, renal and cardiac fibrosis, although the expression and regulation of each PDGF 
ligand appears to be organ-specific also in fibrosis (reviewed in (77)). Interestingly, crosstalk 
has been reported between PDGFs and the pro-fibrotic TGF-β, which seems to contribute to 
the spatial regulation of the different ligands. In the case of PDGF-D, TGF-β has been shown 
to promote signaling in cardiac fibroblasts, but inhibits PDGF-D expression in the lung (78, 
79). The pro-fibrotic potential of PDGF-D in heart and kidney has been demonstrated by 
overexpression studies in vivo (29, 32, 80), and PDGF-D/PDGFRβ signaling is also 
implicated in liver fibrosis (81-83). PDGFRβ-mediated fibrotic responses are executed by 
fibroblasts, myofibroblasts and specialized pericytes, such as hepatic stellate cells and renal 
mesangial cells that have been activated into a fibroblast-like state. Like other pericytes, they 
express PDGFRβ (84), and PDGF-D has been shown to exhibit mitogenic and fibrogenic 
effects on these cells (81, 83, 85, 86). Similar to the other PDGFs, PDGF-D contributes to 
accelerated ECM deposition. In both hepatic stellate cells and cardiac myofibroblasts, PDGF-
D has been shown to upregulate tissue inhibitor of metalloproteinase (TIMP)-1, which 
attenuates matrix metalloproteinase (MMP) activity, thereby decreasing ECM degradation 
(78, 85). Notably, PDGF-D-mediated ECM remodeling is implicated in epithelial-to-
mesenchymal transition (EMT) in cancer (87), a process that is activated also in fibrosis and 
chronic inflammation, (reviewed in (88)). Thus, it is not unlikely that PDGF-D contributes to 
EMT also in fibrosis, but further studies are needed on this subject. 
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In severe fibrosis, the irreversible tissue scarring leads to loss of tissue function, and therefore 
early anti-fibrotic/anti-inflammatory treatments are used. Several studies suggest PDGF-D as 
a suitable therapeutic target in kidney fibrosis, and an anti-PDGF-D monoclonal antibody 
(CR002) has been shown to prevent renal fibrosis in mice (82, 86, 89). Also, the Pdgfd–/– 
mice (presented in Paper I) show reduced renal fibrosis upon experimental induction of renal 
scarring (32). 
1.3.2 Atherosclerosis and other vascular pathologies 
Cardiovascular disease is a major cause of death in the western world. A major risk factor is 
atherosclerosis, a process in which lipid-containing plaques are slowly formed in the vascular 
wall. With time, the plaques may rupture and cause thrombosis or internal bleedings that can 
be life-threatening. Atherosclerotic plaques appear in vessel areas exposed to low shear stress, 
turbulent flow and oscillating flow (reviewed in (24)). Plaques are formed over decades, 
initially through lipid accumulation, followed by endothelial dysfunction and infiltration by 
macrophages and other immune cells into the vascular wall, leading to chronic inflammation. 
In contrast to the healthy vasculature that expresses only low, or undetectable levels, of 
PDGFs, all four PDGF ligands are present in the atherosclerotic vessel wall, and are mainly 
secreted by endothelial cells, vSMCs and macrophages. Also, both PDGF receptors are 
upregulated, and expressed by vSMCs and macrophages ((28, 70) and reviewed in (24)). 
PDGFRβ expression is stronger than that of PDGFRα, and PDGFRβ signaling has been 
shown to be a driving force in the atherogenic process through chemokine signaling that 
induces leukocyte migration (90). In the later stages, active vSMCs play a central role, as they 
proliferate and contribute to the thickening of the vascular wall (reviewed in (91)). 
Atherogenic stimuli (ECM, cytokines, shear stress, reactive oxygen species and lipids) 
promote the switch from a contractile to synthetic phenotype of vSMCs, which is also 
associated with increased PDGFRβ expression and signaling (reviewed in (92)). PDGF-B and 
PDGF-D are both upregulated in endothelial cells exposed to atheroprone blood flow, and 
promote the vSMC phenotypic switch ((93) and reviewed in (24)). For PDGF-D, this is 
mediated through upregulation of the differentiation repressor gene Kruppel-like factor-4, and 
downregulation of contractile proteins, such as α-smooth muscle actin (αSMA) and the 
smooth muscle myosin heavy chain (93). PDGFRβ, PDGF-B and PDGF-D also are induced 
during monocyte-to-macrophage differentiation, and they are all strongly expressed in fatty 
streaks, where PDGFRβ signaling has a strong impact on monocyte/macrophage migration 
(28, 70). Moreover, PDGFs promote stabilization through ECM synthesis, as well as ECM 
remodeling through MMP and TIMP expression (27, 70).  
Notably, recent studies have reported genetic variations in the form of single-nucleotide 
polymorphisms (SNPs) in the PDGFD gene to be associated with coronary artery disease 
(94), and non-hypertensive intra-cerebral hemorrhage (95). This indicates that aberrant 
PDGF-D signaling could be causative in atherogenesis and cardiovascular disease, 
emphasizing the importance of PDGF-D in these conditions.  
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PDGFs in response to vascular injury, rejection and restenosis 
Vascular injury, restenosis and chronic rejection gives rise to conditions that resembles 
atherosclerosis. Upon vessel injury, medial vSMCs migrate from to the intima, where they 
proliferate and switch to a synthetic phenotype in a PDGFRβ dependent manner, resulting in 
neointimal hyperplasia. PDGF-D is upregulated in the intima following angioplasty, and is 
also thought to contribute in this process, next to PDGF-B ((27) and reviewed in (24)). The 
response to chronic cardiac allograft rejection also manifests as a vascular disease, and is 
histologically characterized by concentric luminal stenosis (vascular narrowing) (reviewed in 
(96)). In rat cardiac allografts, PDGF-D, but not PDGF-B, was induced, and increased the 
pro-fibrotic and pro-arteriosclerotic responses leading to chronic rejection, through the TGF-
β1 pathway (97). 
PDGF signaling is of importance also in vascular pathologies involving the blood brain 
barrier integrity in the central nervous system. In stroke, PDGF-C signaling through PDGFRα 
is involved in the acute opening the blood-brain barrier (98, 99). In the chronic disease named 
amyotrophic lateral sclerosis (ALS), high neuronal expression of PDGF-C leads to disruption 
of the blood-spinal cord barrier, and contributes to the early onset of the disease (100). 
1.3.3 Cancer 
In cancer, malignant cells grow in an uncontrolled manner and disrupt normal tissue 
functions. The six hallmarks of cancer established by Hanahan and Weinberg include 
proliferative signaling, evading growth suppressors, resisting cell death, enabling replicative 
immortality, inducing angiogenesis, and activating invasion and metastasis (101). The tumor 
is built up of cancer cells, some of which have stem cell properties, and others have invasive 
capabilities. The tumor microenvironment also contains stromal cells, which include cancer-
associated fibroblasts (CAFs), immune inflammatory cells, endothelial cells and pericytes as 
well as local and bone marrow-derived stromal stem and progenitor cells (reviewed in (102). 
The first connections between PDGFs and cancer arose in 1983, when PDGF-B was 
sequenced and proved to be similar to v-sis, the transforming protein of simian sarcoma virus 
(103, 104). Today, all PDGFs and PDGFRs have been connected to different tumor types, 
and are known to be capable drivers of tumorigenicity through several of the cancer hallmark 
functions; proliferation, angiogenesis and migration (reviewed in (18)). 
PDGF ligand overexpression is seen in carcinomas, tumors of endodermal or ectodermal 
origin, where they promote tumorigenesis and metastasis through recruitment and stimulation 
of stromal mesenchymal cells in a paracrine manner. PDGFs can act through autocrine 
signaling loops in cases where the tumor cells express the receptor (reviewed in (105)). One 
example of autocrine signaling is in dermatofibratoma protuberans, where PDGF-B is 
expressed under a collagen promoter, resulting in a COL1A1/PDGF-B fusion protein from 
which active PDGF-B is cleaved off (106).  
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Constitutionally active receptors are seen in tumors derived from PDGFR-expressing 
mesenchymal cell populations, such as sarcomas and glioblastomas, where they drive 
proliferation and clonal expansion through autocrine signaling (reviewed in (1)). These 
receptors are the result of gene translocations leading to fusion proteins as seen in 
hypereosinophilic syndrome, caused by a FiP1L1-PDGFRα fusion (107), and chronic 
myelomonocytic leukemia, caused by an ETV6-PDGFRβ fusion (108). 
Other types of genetic aberrations in PDGFs and PDGFRs have also been observed to cause 
cancer in the case of PDGF signaling. For PDGFRα, activating point mutations are 
commonly seen in gastrointestinal tumors (GIST) (109), as are gene duplications in 
glioblastomas (110). Overexpression of receptors can also lead to auto-activation (reviewed 
in (111)). 
PDGFRβ signaling in the tumor 
In solid tumors, PDGFRβ expression is mainly confined to stromal cells, such as CAFs, 
vSMCs and pericytes (reviewed in (112)), where PDGFRβ is important in vascular 
stabilization. Tumor vessels are often leaky and fragile due to lack of supporting pericytes 
(reviewed in (102)). Both PDGF-B and PDGF-D, signaling through PDGFRβ, stabilizes the 
vasculature through recruitment of pericytes (113), thereby enhancing vascular function and 
contributing to tumor growth. Pericyte PDGFRβ signaling also provides survival signals to 
the endothelium, for example by upregulating the anti-apoptotic gene Bcl2l2 (114). PDGFRβ 
expression in CAFs is associated with aggressiveness and metastasis, and PDGFRβ signaling 
in both CAFs and pericytes promote high interstitial fluid pressure in tumors through ECM 
interactions (115).  
PDGF-D signaling through PDGFRβ in cancer 
PDGF-D has been reported to be a driver in tumorigenesis in different cancers, such as 
prostate and renal cell carcinoma, pancreatic adenocarcinoma, glioblastoma, schwannoma 
(derived from peripheral glia cells) and melanomas (reviewed in (116)). A major difference 
between the PDGFRβ ligands, PDGF-B and PDGF-D, is that PDGF-D requires proteolytic 
activation, and thus, the enzymes that activate PDGF-D, uPA and matriptase, needs to be 
present in the microenvironment, as has been shown in prostate cancer (9, 11). The role of 
uPA in tumor growth, angiogenesis and metastasis is well studied (reviewed in (117)). For 
matriptase, a feedback loop has been reported, where the activated PDGF-D upregulates 
matriptase (118). Once activated, PDGF-D promotes proliferation, and stimulation of tumor 
cell growth (119). Similar to physiological conditions, PDGF-D and PDGF-B interact with 
the stroma through recruitment of PDGFRβ-expressing cells (vSMCs and macrophages), and 
expression of VEGF and MMPs (120-124).  
Coherently, gene expression profiling has shown that PDGF-D associates with genes active 
in cell adhesion, wounding, and immune system processes (17). Moreover, in dermis, non-
malignant PDGF-D overexpression has been shown to increase interstitial fluid pressure (69). 
Both vascular stability (or impermeability) and high interstitial pressure act to impair drug 
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delivery, as the drug is maintained in the blood stream. Targeting of PDGFRβ signaling 
improves drug delivery and efficacy of chemotherapy (125, 126). Inhibition of PDGF-D has 
been shown to attenuate growth, invasion and angiogenesis in a xenograft model of gastric 
cancer (127). However, in breast cancer PDGF-D blockade also promoted lymphatic 
metastasis by activation of CXCR4 (128). 
PDGF-D in EMT, invasion and metastasis 
PDGF-D and PDGFRβ has also been implicated in invasion and metastasis, through the 
process of EMT, in which epithelial cells lose their apical-basal polarization and cell-cell 
adhesion to acquire a migratory, fibroblast-like phenotype ((129, 130) reviewed in (131)). 
During physiological conditions, embryonic EMT is essential for many developmental 
processes, and in adult tissue it is implicated in wound healing (reviewed in (131)) and in the 
pathological process of fibrosis (reviewed in (88)). In cancer, tumor cells reactivate the 
processes of EMT to become invasive and metastatic which is associated with upregulation 
of mesenchymal markers involved in invasion and migration (reviewed in (132)). PDGF-D 
appears to regulate the process of EMT on several levels, partially through the NF-κB and 
Notch pathways (87, 121). This leads to downregulation of the epithelial adhesion protein E-
cadherin, which in prostate cancer takes place through inhibition of microRNA-mediated 
regulation of the transcription factors Snail, Twist and ZEB1 (133-136). PDGF-D has also 
been shown to upregulate expression of MMPs and the cytoskeletal protein vimentin and 
other mesenchymal markers (124, 137), to promote degradation of basement membranes and 
ECM and thus also angiogenesis, metastasis and invasion. 
PDGF-D and cancer stemness 
There have been different theories on how tumors grow. Today, one that is favored by many 
researchers is the cancer stem cell (CSC) hypothesis. CSCs constitute a small subset of cells 
with the ability form new tumors when implanted into SCID mice, where they both self-
renew and differentiate into more mature phenotypes. These cells only make up a small part 
of the total bulk of cancer cells, but are the main target to treat malignant and metastasizing 
disease (reviewed in (116) and in (102)). The origin of the CSCs is not clear, but they may be 
derived from adult stem cells, or more differentiated progenitor cells, that are present in 
normal tissues, and the source may also differ between tumors (reviewed in (102)). The traits 
of CSC and EMT-transdifferentiated cells overlap to a large extent, and therefore, PDGF-D 
signaling through PDGFRβ has been suggested to be involved also in cancer stemness. It has 
been shown that PDGF-D transformed NIH-3T3 fibroblasts show CSC features, such as 
anchorage-independent growth in soft agar and ability to induce tumors in nude mice (119). 
Moreover, several studies have reported that high expression of PDGF-D induces EMT, and 
SCS-like capabilities in cancer cells, thus contributing to tumor aggressiveness (136, 138). 
Recently, we published a study showing that in a RIP1-TAg2 model of neuroendocrine 
pancreatic cancer, the tumours in Pdgfd–/– mice developed more slowly than those in Pdgfd+/+ 
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littermates. The possibility that this delay is because of altered CSC capacity is further 
discussed in Paper II. 
  17 
1.4 NEUROPILIN 1 
Neuropilin 1 (NRP1) and NRP2 are multifunctional trans-membrane co-receptors for 
members of the class-3 semaphorins (SEMA3) in neuronal axon guidance and vascular 
endothelial growth factors (VEGFs) in angiogenesis. However, interactions of NRP1 with 
ligands from other signaling systems, such as TGF-β1, hepatocyte growth factor (HGF) and 
fibroblast growth factor (FGF) have been reported (reviewed in (139)).  
There is a growing body of evidence showing that PDGFR signaling can be modified by 
NRP1 (42, 43, 140-144), and in Paper III, we provide evidence that NRP1 can act as a co-
receptor for PDGF-D. In this section, NRP1 and its functions as a co-receptor for the 
structurally related members of the PDGF/VEGF superfamily are described.  
1.4.1 Structure, function and expression of NRP1 
The NRPs consists of seven sub-domains where the first five are extracellular; two CUB 
domains (a1 and a2), two coagulation factor V/VIII domains (b1 and b2) and a meprin, A5 µ-
phosphatase domain (c). Following the trans-membrane domain, NRPs contain a short 
cytosolic tail with a PDZ (Post synaptic density protein, Drosophila disc large tumor 
suppressor, and Zonula occludens-1 protein) binding domain (reviewed in (145)). Full-length 
NRP1 protein is present as a 130 kDa species, but there are also several splice variants that 
are less studied, and will not be discussed in this thesis (reviewed in (146)).  
Ligand binding occurs at different sites of NRP1; SEMA3A binding requires the first three 
NRP1 sub-domains; a1, a2, and b1, whereas VEGF-A binds primarily to a negatively charged 
cleft in the b1 domain but also to the b2 domain (147, 148). VEGF-A165 binds to NRP1 
through a [KPRR] motif in the C-terminus, where the last arginine is crucial for binding (148, 
149). The C-terminal arginine is shared by most of the NRP1-binding VEGF isoforms 
(reviewed in (146)). It has been suggested that NRP1 is present as homo- or heterodimers, but 
it is also possible that they oligomerize to form high-affinity binding sites for ligands (150).  
NRP1 is expressed by a variety of cells, including vSMCs (143), endothelial cells, neurons, 
and different epithelial cells (reviewed in (151)). In the vasculature, NRP1 is mainly 
expressed by arterial endothelial cells, and during angiogenesis also by neural progenitors and 
macrophages. NRPs are also commonly expressed by tumor cells and tumor vasculature 
(reviewed in (152)). Studies of knockout and transgenic mouse models have shown that 
NRP1 is crucial for neuronal, cardiac and vascular development, and Nrp1–/– animals die at 
E10-12.5, with VEGF-A/NRP1 signaling-dependent defects in angiogenesis, vascular 
branching and topographic origin of the coronary arteries (153-155). It is also clear that 
NRP1 expression requires tight regulation; when overexpressed, NRP1 resulted in a lethal 
(E12.5) phenotype with excessive capillary growth, hemorrhages, cardiac malformation and 
neuronal defects (156). Also, the cytoplasmic part of NRP1 is not needed for survival, as 
mice expressing a truncated NRP1 protein displayed a mild phenotype with increased retinal 
arteriovenous crossings, and reduced number of arteries in heart, kidney and skeletal muscle 
(157, 158).  
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In conclusion, the NRP1 co-receptor has a vital role in arteriogenesis and angiogenesis, and it 
is expressed in PDGFRβ-expressing vSMCs and neighbouring endothelial cells. Thus, the 
correlating spatio-temporal expression of NRP1, PDGFRβ and the PDGFRβ ligands would 
facilitate their interaction. 
1.4.2 NRP1-mediated modulation of signaling 
Neuropilins are mainly modulators of signaling (reviewed in (146)), and appear to induce 
situation-specific responses. Enhancing functions are generally seen for SEMA3, VEGF-A, 
and PDGF ligands, while NRP1 has an inhibitory function for TGF-β. Interestingly, in 
angiogenesis, NRP1 enhances the endothelial tip cell phenotype through VEGFR2 signaling 
while it inhibits the stalk cell phenotype through inhibition of TGF-βR1/2, thus driving two 
different responses in the same cell type (reviewed in (159)). How NRPs exert their functions 
is still unclear, but suggested mechanisms include ligand capture, receptor inhibition, and 
competitive binding between ligands (160-162). The intracellular alteration of responses is 
mediated through enhanced receptor trafficking or enhanced cell migration or adhesion 
through direct or indirect interaction with integrins (141, 143, 163, 164). 
Signaling occurs in both cis and trans. So far, signaling in trans has mainly been reported in 
tumor cells, where it counteracts angiogenesis by interference with VEGFR2 trafficking. 
NRP1 signaling in trans can also mediate adhesive functions, and thereby modulate the 
signaling time frame, or enhance cell-cell contact (165). In paper III, we show that PDGF-D 
induces complexes between NRP1 and PDGFRβ, both in cis and in trans, which further 
extends the possibilities of modulation of PDGF-D signaling.  
NRP1 in PDGF signaling 
There is an increasing amount of data showing that NRP1 regulation of PDGF signaling 
appears to be important for vSMC function, and possibly also endothelial-mural cell 
communication (42, 43, 140-144). As discussed previously, the main PDGF ligand in the 
vasculature is PDGF-B, and several studies report that NRP1 can modulate PDGF-B-induced 
migration of vSMCs through tyrosine phosphorylation of the intracellular integrin adaptor 
protein p130Cas (141, 143, 166). NRP1 has also been reported to participate in PDGF-
mediated recruitment and differentiation of MSCs into pericytes (140). Consistently, several 
studies have shown that impairment of NRP1 signaling disrupted PDGF-B-mediated vSMC 
migration (43, 142-144). NRP1 implications in vSMC-related diseases also appear to overlap 
with the indications for PDGFs; NRP1 contributes to neointimal hyperplasia, and promote the 
synthetic phenotype of vSMCs, through a pathway that is likely PDGF-dependent (144). 
NRP1 is also upregulated in response to PDGF-B, thus reinforcing NRP1-PDGF signaling 
(43). 
Physical interactions between NRP1 and PDGFRs have been suggested, but the specific 
mechanisms for modulation of PDGF/PDGFR signaling by NRP1 are uncertain. Co-
immunoprecipitation experiments have shown that NRP1 forms complexes with PDGFRα 
and PDGFRβ in mesenchymal stem cells when stimulated with PDGF-A or PDGF-B, thus 
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indicating that NRP1 could act as a co-receptor for PDGFs (42). However, there have been 
contradictory reports on whether PDGF-B can bind to NRP1 (43, 143). These controversies 
may be explained by the presence of an additional, 250 kDa form of NRP1, which is 
glycosylated between the “b2” and “c” domains by chondroitin sulfate (CS) or heparan 
sulfate glycosaminoglycans. The CS-NRP1 enables cell-specific regulation of binding, and is 
present in vSMCs and certain tumor cells, where it has been shown to promote PDGF 
signaling. At the same time CS-NRP1 also inhibits VEGF-A binding to VEGFR2 (167). 
We have found that PDGF-D is a much more specific ligand for the 130 kDa NRP1 species, 
than PDGF-B, and that PDGF-D binds NRP1 with about the same affinity as VEGF-A165. 
This finding, and the role of NRP1 as a co-receptor for PDGF-D are discussed in paper III. 
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2 AIMS OF THIS THESIS 
With the exception of PDGF-D, the PDGFs and PDGFRs have been well studied in different 
mouse models with genetic alterations. The aim of this thesis is to explore the physiological 
role of PDGF-D in health and disease, mainly by analyses of the Pdgfd–/– mouse strain. 
The specific aims include: 
• To map the expression of Pdgfd, using the LacZ reporter gene in the Pdgfd knockout 
construct (Paper I) 
• To investigate the phenotype the Pdgfd–/– mice (Paper I) 
• To evaluate the role of PDGF-D ablation in a genetic model of cancer (Paper II) 
• To characterize the binding of NRP1 to PDGF-D, and the ability of PDGF-D to 
induce complex formation between NRP1 and PDGFRβ (Paper III) 
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3 PAPERS AND DISCUSSION 
To highlight central findings and rationale, each paper will be summarized and discussed 
below. Methods and results are described in detail in the respective papers. 
3.1 PAPER I – MICE LACKING PLATELET-DERIVED GROWTH FACTOR D 
DISPLAY A MILD VASCULAR PHENOTYPE 
The roles of PDGF-A, -B and -C, and their signaling through PDGFRs have been studied 
through a large number of reporter gene, transgenic and knockout animal models, which have 
contributed greatly to the understanding of PDGF biology. However, the role of PDGF-D is 
still obscure, and prior to this study, there were no reports of reporter genes or knockout mice 
for PDGF-D.  
In a ligand-receptor system such as the PDGF system, the phenotype of the ligands is 
expected to match that of the receptor, as seen for the Pdgfa–/– and Pdgfc–/– phenotypes 
compared to that of Pdgfra–/–. The phenotypes of PDGF-B and PDGFRβ are very similar, and 
therefore, the phenotype of Pdgfd–/– mice was expected to be milder. However, PDGF-D 
exerts its functions through PDGFRβ, which has a very distinct role in vSMCs/ pericytes, 
where it is needed for mural cell recruitment and proliferation during angiogenesis, and 
maintenance of the vascular homeostasis in the adult. PDGF-D expression has been reported 
in the vasculature previously (8, 27-29, 31), although there have been some inconsistencies in 
the reports of expressing cell types. PDGF-D has also been implicated in a number of 
vascular pathologies, and therefore, the vasculature was a candidate site of action.  
In this study, we present the Pdgfd–/– mouse strain, which is viable, fertile and show no gross 
abnormalities, in contrast to the other PDGF knockouts. The mouse has a normal life span, 
which enables future studies of PDGFRβ signaling in the adult settings. The study aim was to 
map the expression of Pdgfd through the LacZ reporter gene that was inserted in the targeted 
allele, and to explore the physiological functions of PDGF-D/ PDGFRβ signaling, with the 
vasculature as a starting point. 
To identify organs of interest for PDGF-D function, we performed a general expression 
analysis on mRNA level, where adrenal gland, spinal cord, aorta, heart, uterus, cerebellum 
and lung were identified as high expression organs. These are all highly vascularized organs, 
and also, the vasculature was pointed out as a common expression site of Pdgfd between 
organs in our histology based reporter gene studies, thus supporting the notion that PDGF-D 
should have a vascular function. In concordance with previously published studies (27, 29), 
Pdgfd expression was seen predominantly in the endothelial compartment, but also occurred 
in vSMCs. We also confirmed that the Pdgfd expression was more prominent in arteries than 
in veins and frequently found in foci around vessel bifurcations. Moreover, there appeared to 
be a spatio-temporal regulation of expression, as it went from a strong, exclusively arterial 
expression at postnatal day (P4) to become more widely spread in adult vasculature, which 
could be representative of both endothelial-to-mural cell and mural cell autocrine signaling. 
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In total, our study confirms that PDGF-D can be expressed in both endothelial cells and 
vSMCs, and that the expression differs depending on vessel type and stage of life.  
The other PDGFRβ ligand, PDGF-B, is secreted by the endothelium in its active form but its 
expression is low or undetectable in the healthy, dormant endothelium. As PDGFRβ is 
expressed in vSMCs, a possible function for PDGF-D could be in vascular maintenance or 
endothelial-to-mural cell signaling, where it would be activated upon need. Therefore, we 
examined vascular morphology and pericyte coverage. While we found no changes in 
endothelial appearance, nerve/glial antigen 2 (NG2)-expressing pericytes appeared 
disorganized and less attached in the cardiac vasculature of Pdgfd–/– mice. We verified the 
downregulation of NG2 also on mRNA level by qPCR, and also found another mural marker, 
desmin, to be downregulated. To explore whether the deviations in NG2+ vasculature had 
implications on Pdgfd–/– heart function, we performed a broad gene-expression analysis, 
including different immunological, developmental and vascular genes. We found a 
downregulation of Gata4 and Notch1 mRNA, two genes that regulate cardiac development 
and growth, cell fate, and maintenance of cardiac function in adult tissue, and thus, we 
continued the search of a cardiac phenotype. Clinical chemistry analysis revealed a modest 
increase in Pdgfd–/– serum concentrations of Ca2+, and we observed a trend towards smaller 
hearts in the Pdgfd–/– animals, compared to wildtype controls. Finally, we also detected a 
slight, but significant, elevation in both systolic and diastolic blood pressure compared to 
wildtype controls, suggesting a peripheral vascular or cardiac defect in Pdgfd–/– mice.  
As the Pdgfd–/– animals survive, we did not expect to find any major heart defects. However, 
the slight increase in blood pressure indicates that something is different in the vasculature or 
the regulation of blood pressure, and it is tempting to speculate that it is related to the 
abnormalities seen in cardiac NG2+ pericyte morphology and/or serum Ca2+. It could also be 
connected to cardiac output, mean arterial pressure or peripheral resistance, which also affect 
the blood pressure blood pressure. It would be interesting to see whether anomalies are 
present also in other PDGFRβ-expressing cells, such as epithelial cells, of the Pdgfd–/– mice, 
and to assess cardiac output, and other cardiac parameters by echocardiography. 
In summary, we present a Pdgfd knockout mouse strain with a mild vascular phenotype, 
thereby completing the PDGF “knockout family”. The Pdgfd–/– mice will be a great aid in 
studying the physiological and pathological roles of PDGF-D/PDGFRβ signaling, during 
both developmental and in adult stages of life. We provide new insights on both expression 
pattern and function of PDGF-D, suggesting a role in regulation of arterial blood pressure. 
We also describe a possible role for PDGF-D in mural cell physiology and regulation of 
vascular homeostasis. 
3.2 PAPER II – FUNCTIONAL MALIGNANT CELL HETEROGENEITY IN 
PANCREATIC NEUROENDOCRINE TUMORS REVEALED BY TARGETING 
OF PDGF-DD 
Tumors are heterogeneous, and consist of cancer cells of varying level of differentiation, and 
varying composition of the stromal compartment. PDGFs are commonly deregulated in 
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cancer, and do not only act on the tumor cells, but also on PDGFR-expressing stromal cells, 
such as CAFs, pericytes and vSMCs (reviewed in (112)), where they drive cellular processes 
such as proliferation, survival and motility, thereby promoting tumor growth and invasion 
(reviewed in (1)). Pharmacological blockade of PDGF signaling is routinely used for 
treatment of a diversity of malignancies (105). PDGF-D is upregulated in a number of 
different tumors, and is known to promote tumor progression through ECM remodeling and 
deposition. Lately, PDGF-D has also been reported to be involved in EMT and to support of 
cancer stem cells (130, 133, 136-138).  
The aim of this study was to investigate PDGF-D and PDGFRβ signaling in a heterogeneous 
tumor. For this purpose, we bred the Pdgfd–/– animals with the RIP1-TAg2 mouse model of 
pancreatic neuroendocrine tumors (PanNET). The RIP1-TAg2 mice are engineered to express 
the oncogenic SV40 T antigen under the rat insulin promotor in the pancreatic islets, leading 
to hyperproliferation of islets and tumorigenesis. We found that PDGF-D deficiency delayed 
tumor growth by reducing cell proliferation, and thereby prolonging survival.  
RIP1-TAg2 tumor formation has been studied previously in mice lacking the PDGF-B 
retention motif (Pdgfbret/ret) (168). In these mice, pericyte recruitment is severely disturbed in 
both normal and tumor vasculature, and has also been connected to an increased rate of 
metastasis. In consistence with our findings in Paper I, the expression of PDGF-D appeared 
to be mainly vascular in RIP1-TAg2; Pdgfd+/- tumors. While vascular insufficiency and low 
presence of cytokine producing cells are common reasons for tumor growth stagnation, no 
effects were seen on angiogenesis, pericyte recruitment or immune cell infiltration. Also, the 
lack of PDGF-D did not affect the invasive nor metastatic properties of RIP1-TAg2 tumors. 
These findings are in coherence with our findings in Paper I, that the Pdgfd–/– mice does not 
display any gross vascular abnormalities. Moreover, the metastatic properties are tightly 
connected to vascular integrity, and as the RIP1-TAg2; Pdgfd–/– tumor vessel morphology 
was unaltered, the lack of alterations in metastatic frequency was not surprising. 
To better understand the delayed growth in PDGF-D deficient tumors, we did an expression 
profiling by qPCR that showed an upregulation of Pdgfb in RIP1-TAg2; Pdgfd–/– mice, 
compared to RIP1-TAg2; Pdgfd+/+ controls. This upregulation was likely aimed to make up 
for the lack PDGF-D, but clearly not enough to compensate for the reduced tumor growth, 
thus indicating a special role for PDGF-D in tumor development. Therefore, we explored the 
possibility of PDGF-D-responsive cells outside of the vascular compartment. By co-stainings 
of insulin and PDGFRβ, in RIP1-TAg2; Pdgfd+/+ tumors, and fluorescence-activated cell 
sorting (FACS) analysis, we were able to identify a small subset of non-vascular tumor cells 
that were strongly expressing PDGFRβ, and thus responsive to PDGF-D. Consistently, a rare 
PDGFRβ+ subset of cells was also present in the malignant βTC3 cell line, derived from 
RIP1-TAg2 tumors. This was a novel and highly interesting finding, as PDGFRβ expression 
has been thought to be restricted to mural cells in the RIP1-TAg2 model (169). Interestingly, 
the βTC3 cells increased proliferation and formed a larger number of tumor spheroids upon 
treatment with PDGF-D, compared to PDGF-B, indicating a mechanistic difference between 
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PDGF-D and PDGF-B signaling. It is possible that the newly discovered PDGF-D co-
receptor, NRP1, is involved in signaling modulation through altering, enhancing or 
prolonging signaling response. The function of NRP1 in modulation of PDGF-D signaling is 
addressed in Paper III.  
To investigate the tumorigenic properties of PDGFRβ+ βTC3 cells, FACS sorted cells that 
were either PDGFRβ+ or PDGFRβ– were subcutaneously transplanted into immunodeficient 
mice, and yielded tumors that were histologically indistinguishable from each other. Another 
FACS analysis showed that tumors formed from PDGFRβ– cells had the same proportion of 
PDGFRβ expression as tumors formed from PDGFRβ+ cells, thus indicating an inter-
conversion between these two subsets of cells. We also verified that a subpopulation of 
PDGFRβ+ malignant cells is present also in human PanNET. 
Taken together, we show that PDGF-D may contribute to PanNET tumor growth through 
angiocrine signaling, reinforcing functional malignant cell heterogeneity by stimulation of a 
rare PDGFRβ+ subset of tumor cells, which then engage in paracrine crosstalk with 
neighboring PDGFRβ– cells to drive tumor progression. We also show that PDGFRβ– tumor 
cells can switch into a PDGFRβ+ phenotype, to maintain a constant level of PDGF-D-
responsive cells, thereby securing local access to tumorigenic signals. It would be interesting 
to further characterize NRP1 expression and its putative role in regulation of PDGF-D 
signaling in the progression of PanNET. Lastly, the notion that PDGFRβ+ malignant PanNET 
cells exist will likely impact the treatment regimens used for this type of cancer in the clinic. 
Sunitinib and other PDGFRβ-targeting drugs might not only affect the vascular function, but 
also this rare population of highly tumorigenic cells, thus positioning these drugs as even 
more potent treatment options for PanNET than previously thought.  
3.3 PAPER III – NEUROPILIN 1 IS A CO-RECEPTOR FOR PLATELET-
DERIVED GROWTH FACTOR (PDGF)-D/PDGF RECEPTOR (PDGFR)β 
SIGNALING 
The need for PDGF-B signaling through PDGFRβ signaling in angiogenesis and vascular 
homeostasis is well documented. However, the role of PDGF-D is less clear. The existence of 
PDGF-D as a PDGFRβ specific ligand, together with its need for extracellular activation, and 
the pathological implications from overexpression studies confirm that, once activated, 
PDGF-D is very potent in altering ECM homeostasis and other processes. Indeed, PDGF-D 
can induce responses separate from those induced by PDGF-B. As shown in Paper II, PDGF-
D, but not PDGF-B, induces signaling in rare PDGFRβ-expressing tumor cells, and 
contributes to tumor progression in PanNET in a manner that cannot be explained by 
differential activation. This could, however, be explained by modulation of signaling by a co-
receptor. 
There is a growing body of literature showing that NRP1 can modulate the signaling of both 
PDGFRs (42, 43, 140, 142, 143), but it does not bind to PDGFRβ directly. Also, the affinity 
of PDGF-B binding to non-glycosylated NRP1 appears to be low (42, 143). Hence, this opens 
up for an additional, co-receptor-modulated role of PDGF-D as the other ligand for PDGFRβ.  
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In this study, we discovered that PDGF-D shares some structural features with NRP1 binding 
VEGF ligands. In similarity with the NRP1-binding VEGF-A isoforms, VEGF-C, and 
VEGF-D, the PDGF-D growth factor domain has a conserved cysteine knot structure, 
accompanied by a C-terminal positively charged arginine residue, which in the VEGF ligands 
is crucial for NRP1 binding. However, these structural features are not seen in PDGF-B.  
We show that PDGF-D specifically binds to NRP1 and induces PDGFRβ/NRP1 complex 
formation in cells, both in cis- and in trans-conformation, and that binding leads to 
phosphorylation of PDGFRβ, thus inducing downstream signaling. We also confirm that 
NRP1 binding of PDGF-B is only limited. Moreover, upon PDGF-D-stimulation of cultured 
cells, PDGF-D, NRP1 and PDGFRβ were co-clustered and internalized together, suggesting 
that NRP1 alters the trafficking of PDGFRβ. A similar mechanism has previously been 
shown for NRP1 in modulation of VEGF-signaling (170).  
To our knowledge, this is the first study to assess the role of the novel PDGFs (PDGF-C or 
PDGF-D) as targets for NRP1 modulation. It makes sense that PDGF-D would be the 
preferred PDGFRβ ligand for NRP modulation, considering that PDGF-D expression and 
activation are not coupled. With these new insights into the co-receptor function of NRP1 for 
PDGF-D/PDGFRβ signaling, our study provides a mechanistic basis for differential signaling 
between PDGF-D and PDGF-B. It also adds complexity to the current hypotheses on NRP1 
modulation of PDGF signaling and might even challenge some conclusions drawn from the 
previous reports. 
Altogether, these findings will lead to a better understanding of the role(s) of PDGF-D, and 
thereby to improved development of tailored therapeutics for conditions where vascular 
function is disrupted, such as atherosclerosis and cancer. 
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4 FUTURE PERSPECTIVES 
In the work included in this thesis, we present the Pdgfd–/– mouse strain, and thereby the 
“PDGF family of knockouts” is finally complete. The mild phenotype of the Pdgfd–/– mouse 
strain (described in Paper I) was not surprising to us, given the similarity between the PDGF-
B and PDGFRβ phenotypes, indicating a certain amount of redundancy between PDGF-D 
and PDGF-B during physiological conditions. However, PDGF-B and PDGF-D signaling 
mechanisms differ in that PDGF-B is secreted in its active form, and retained close to the cell 
of origin through ECM binding, while PDGF-D is released in an inactive, diffusible form. 
Thus, PDGF-D expression and activation are uncoupled, and require the presence of 
additional activating factors, indicating a potent inducible function of PDGF-D, which might 
be important under specific conditions. Moreover, the identification of NRP1 as a co-receptor 
for PDGF-D, and its ability to form signaling complexes with PDGFRβ also in trans 
indicates that NRP1 does not only modulate signaling in the PDGFRβ -expressing cell, but 
also enables and potentiates cell-cell communication via direct adhesion to neighbouring 
NRP1-expressing cells. In my mind, this implies that a “main” function of PDGF-D is yet to 
be found. 
In the vasculature, NRP1 is expressed by endothelial cells, and PDGFRβ by mural cells, thus 
the proposed signaling in trans is highly relevant for the communication between these two 
cell types. Interestingly, PDGF-D is commonly expressed around vascular bifurcations, and 
we have hypothesized that it is involved in regulation of local blood flow. Could it be that 
endothelial NRP1 acts in complex with mural PDGFRβ to regulate vascular contraction? This 
could be studied through an aortic ring assay, with and without PDGF-D stimulation. Another 
idea is that extra stability is needed in these areas due to turbulent blood flow, and that this is 
mediated through the NRP1-PDGF-D-PDGFRβ trans complexes.  
It is also possible that PDGF-D has a role in angiocrine signaling with effects on cells in the 
tissues surrounding the vessels that could be somewhat similar to the mechanism described in 
Paper II. In this study, we present evidence that vascular PDGF-D reinforces the proliferative 
paracrine signaling of a rare population of PDGFRβ-expressing tumor cells to neighbouring 
tumor cells. Thus, the main site of action for PDGF-D might not be the vasculature, but some 
other tissue at some distance from the vessel. Interestingly, PDGFRβ expression has been 
reported in non-vascular progenitor cell populations and PDGF-D has been connected to stem 
cell signaling also in non-malignant conditions (60, 73, 74). Our reporter gene study indicated 
prominent expression of PDGF-D in several different epithelial tissues. Whereas epithelial 
cells are known to produce the PDGFRα-specific ligand PDGF-A (reviewed in (2)), the role 
of PDGFRβ in epithelial cells is not clear. However, the strong reporter gene expression of 
the PDGFRβ-specific PDGF-D is indicative of a role also for PDGFRβ signaling in the 
epithelium, possibly in a long-range paracrine manner similar to angiocrine signaling. 
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Now, the next step is to challenge the Pdgfd–/– mice, to see if it has any phenotypic deviations 
compared to the wildtype mice. We have several projects involving challenges going on in 
the lab, and Paper II is derived from one of them. Another condition where PDGF-D is 
strongly implicated is atherosclerosis, and the SNPs in PDGF-D associated with coronary 
artery disease indicate that dysregulation of PDGF-D aggravates the disease. In an ongoing 
study, we have crossed the Pdgfd–/– mice with the athero-prone ApoE–/– mice. It will be very 
interesting to analyze the aortas from these mice to see if the plaques are differently 
constituted, and what cell populations that are altered. 
In any case, it is possible that NRP1 holds the key to the function of PDGF-D, and this will 
be considered in future studies.  
 
Figure 3. Possible physiological signaling modes for PDGF-D. PDGF-D is expressed by endothelial cells and pericytes, 
and activated by uPA, matriptase or possibly other unknown serine proteases. uPA is expressed by endothelial cells. (I) 
Short range paracrine or autocrine signaling in the vasculature. Pericytes express PDGFRβ, and PDGF-D can either bind 
its receptor directly or engage the co-receptor NRP1 to form a complex. Complex formation can occur both in cis and in 
trans. (II) Angiocrine signaling, from the vasculature to cells in the surrounding tissue. The latent PDGF-D is diffusible 
and therefore not retained in the vasculature. Hypothetically, rare cells in the tissue express PDGFRβ, and the same cells, 
or surrounding cells express activating serine proteases and the co-receptor NRP1. Thus, NRP1-modulation of PDGF-
D/PDGFRβ signaling in cis or trans could occur. 
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